Pay in 4 interest-free payments of $5.38 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
Vyvanse reduces symptoms of impulsivity and inattention
Patients should: Weigh themselves once weekly at the same time and under consistent conditions Record measurements in a diary or app to identify trends Aim for gradual weight loss (NHS advises 0.51 kg per week is generally safe and sustainable) Understand that response to GLP-1 therapy varies between individuals Report unexpected rapid weight loss or gain to their healthcare provider It is important to recognise that weight loss may plateau after several months, and this does not necessarily indicate treatment failure
In a 68-week clinical trial, participants on Wegovy lost an average of 14.9% body weight compared to 2.4% in the placebo group
It enhances the secretion of insulin and glucagon-like peptide-1 (GLP-1) and reduces glucagon secretion
Research presented at the European Congress on Obesity in 2024, for instance, found that people who gradually reduced their dose to zero (over an average of nine weeks) maintained a stable body weight in the first 26 weeks after tapering
